Moderna stock has delivered a strong 126.0% return over the past year, yet the company still screens as expensive on broad valuation checks, so investors are weighing a sharp share price recovery against signals that the stock is not a clear bargain.

• Over the last 1 year, Moderna has returned 126.0%, which puts recent share price momentum front and center for anyone assessing whether current levels are stretched.
• The recently announced Phase 1 trial of the mRNA-1469 vaccine for Bundibugyo ebolavirus may support investor expectations for the pipeline, while execution risk around clinical outcomes and eventual commercial uptake can still limit how much value the market will ascribe today.
• Moderna scores 0 out of 6 on Simply Wall St's broader valuation checks, which means the stock currently leans expensive rather than looking like a clear bargain on metrics such as price multiples and assets 0/6.

The issue now is whether Moderna's recent share price strength leaves enough upside to justify the valuation that investors are paying today.

Does Moderna Look Pricey on Sales?

P/S is often a useful cross check for Moderna because the company is focused on commercialising its mRNA platform and reported free cash flow is still negative.

Moderna trades on a P/S multiple of about 11.3x. That is slightly above the broader biotech industry average of 10.9x and also ahead of the peer group average near 5.4x. The model based fair P/S ratio sits much lower at around 2.6x. This gap is very wide, so it is better read as a warning flag that the framework is penalising current losses and risk rather than as a precise target level.

Despite the recent news on the Bundibugyo ebolavirus vaccine trial supporting sentiment around the pipeline, the P/S multiple still prices Moderna at a steep premium to both peers and the model fair ratio.

On the P/S multiple, Moderna stock currently appears overvalued.

The Moderna Narrative: What Would Justify Today's Price?

Simply Wall St Narratives build on Moderna's valuation puzzle by outlining which paths for revenue growth, margins and earnings would need to occur for the stock to be worth materially more or less than today's price. These Narratives are available on the Community page. Each narrative links its number to a clear view of how Moderna's growth, profitability and risks could evolve, which you can revisit as new information becomes available.

Community views on Moderna sit far apart, with one group focused on long term vaccine and oncology potential and another worried that expectations already look demanding.

Bull case: 20% undervalued

"The deployment of advanced AI and digital automation across all functions is transforming R&D, manufacturing, and commercial processes. Ongoing improvements are sharply reducing development timelines and operational costs, which can lift net margins and enable faster, more profitable product launches…"

Bear case: 43% overvalued

"The company's strategy to seek external partners or financing (rather than self-funding) for key pipeline assets in high-potential but expensive clinical areas (like latent vaccines and rare diseases) reflects limited internal capital flexibility. This may restrict long-term pipeline breadth, reduce the probability of blockbuster diversification, and ultimately limit long-term revenue growth and earnings potential…"

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

The Bottom Line

For Moderna, the key takeaway is that the stock screens as overvalued on market multiples, with a very wide gap between the current P/S and the model fair ratio. That gap reflects how much optimism is already baked into the price despite ongoing losses and execution risk across the pipeline. From here, the real swing factor is whether Moderna can convert its mRNA platform and newer vaccine programs into durable revenue and margin strength that justifies this premium, or whether expectations eventually reset closer to peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.